Literature DB >> 26199352

Fatal toxic epidermal necrolysis in a patient on teriflunomide treatment for relapsing multiple sclerosis.

Gaspard Gerschenfeld1, Amandine Servy2, Laurence Valeyrie-Allanore2, Nicolas de Prost3, Jérôme Cecchini4.   

Abstract

We report a case of toxic epidermal necrolysis in a 46-year-old woman on teriflunomide treatment. Such a severe adverse cutaneous drug reaction with this new therapy for relapsing forms of multiple sclerosis should be early recognized in order to ensure the rapid withdrawal of the drug.
© The Author(s), 2015.

Entities:  

Keywords:  Teriflunomide; adverse effect; multiple sclerosis; toxic epidermal necrolysis

Mesh：

Substances：

Year:  2015        PMID： 26199352     DOI： 10.1177/1352458515596601

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


  5 in total

Review 1.  Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis.

Authors:  Joachim Havla; Clemens Warnke; Tobias Derfuss; Ludwig Kappos; Hans-Peter Hartung; Reinhard Hohlfeld
Journal:  Dtsch Arztebl Int       Date:  2016-12-26       Impact factor: 5.594

Review 2.  Cutaneous Adverse Effects of Neurologic Medications.

Authors:  Eman Bahrani; Chloe E Nunneley; Sylvia Hsu; Joseph S Kass
Journal:  CNS Drugs       Date:  2016-03       Impact factor: 6.497

Review 3.  From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis.

Authors:  Lilian Aly; Bernhard Hemmer; Thomas Korn
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

Review 4.  The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.

Authors:  Gabriel Pardo; David E Jones
Journal:  J Neurol       Date:  2017-09-06       Impact factor: 4.849

Review 5.  Multiple sclerosis--new treatment modalities.

Authors:  Rocco Totaro; Caterina Di Carmine; Carmine Marini; Antonio Carolei
Journal:  Indian J Med Res       Date:  2015-12       Impact factor: 2.375
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.